Intravenous GP-1-531 adenosine regulating agent: Began Phase I trial in the U.K. of the intravenous form owned by ARAM; the oral form, owned by GNSA, willl be t

Gensia Inc. (GNSA), San Diego Aramed Inc. (ARAM) Product: Intravenous GP-1-531 adenosine regulating agent Indication: Cardioprotective during ischemia in angina, heart attack, and surgery Status: Beg...